ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1243

Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms

Hitomi Kobayashi1, Isamu Yokoe2, Hiroshi Sato1 and Yasuyuki Kobayashi3, 1Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, 2Nihon University School of Medicine, Tokyo, Japan, 3Radiology, St.Marianna University School of Medicine, Kawasaki, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Magnetic resonance imaging (MRI), rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to test the hypothesis that the powerful anti-inflammatory effect of anti-interleukin 6 (tocilizumab: TCZ) therapy might lead to a reduction in left ventricular (LV) dysfunction in patients (pts) with RA. We sought to measure LV regional function by using a cardiac magnetic resonance imaging (CMR) approach in RA pts without cardiac symptoms, and also to evaluate the changes in these measurements at 52 wks of TCZ treatment.

Methods: This was an open-label prospective pilot study to directly evaluate the effect of TCZ on LV function in RA pts without a clinical diagnosis of cardiovascular disease. Consecutive RA pts with active disease and healthy control subjects were enrolled. The RA pts each had inadequate clinical response to non-biologic DMARDs or non-TNF directed therapy, and were prescribed TCZ therapy (8 mg/kg IV every 4 wks). All subjects underwent baseline evaluation of LV function, as measured by non-contrast CMR on a 1.5 T scanner. Peak systolic regional radial strain (Err, %) was calculated by feature tracking of cine MRI in the six segments of the mid-slice of LV. After the baseline (BL) CMR, treatment with the prescribed TCZ was initiated and pts were followed for 52 wks. Pts underwent follow-up CMR evaluation at 52 wks of treatment with TCZ. We examined the differences in peak Err between the control subjects and RA pts. We compared peak Err of RA pts at BL and at 52 wks, and determined the association of peak Err with disease activity and severity measures.

Results: All RA pts received TCZ treatment for 52 wks. We compared 11 RA pts (100% female; mean age 52.6±10.4 y) at BL and at 52 wks, with 10 non-RA controls (100% female; mean age 55.7±4.6 y). DAS28-ESR, SDAI, and Swollen Joint Count (SJC) were significantly lower in RA pts at 52 wks than at BL (p<0.0001, p<0.0001, p=0.003, respectively). Mean peak Err in RA pts at BL was significantly lower than in normal subjects (0.58±0.13 vs. 0.69±0.10; p=0.04); mean peak Err in RA pts at 52 wks was not significantly different from those of normal subjects (0.65±0.12 vs. 0.69±0.10; p=0.56) (figure). Mean peak Err tended to be lower at BL than at 52 wks, but not significantly (p=0.26). Percentage change of mean peak Err in RA pts was significantly associated with percentage change of SJC (r=0.74, p=0.009) and DAS28-ESR (r=0.70, p=0.017).

Conclusion: Our findings suggested sub-clinical LV regional dysfunction in RA pts without cardiac symptoms. Furthermore, we demonstrated that improvements in LV regional function by TCZ treatment correlated with reduction in measures of systemic inflammation and RA disease activity. This suggests that systemic inflammation contributes to myocardial dysfunction in RA.


Disclosure:

H. Kobayashi,
None;

I. Yokoe,
None;

H. Sato,
None;

Y. Kobayashi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-tocilizumab-treatment-on-regional-left-ventricular-function-as-assessed-by-cardiac-magnetic-resonance-imaging-in-rheumatoid-arthritis-patients-without-cardiac-symptoms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology